HC asks govt to fix coronary stents MRP by March 1 next year

Image
Press Trust of India New Delhi
Last Updated : Dec 22 2016 | 7:13 PM IST
The Delhi High Court today asked the Centre to fix by March one next year the maximum retail price (MRP) and a ceiling price of coronary stents used to treat narrowed or weakened arteries in the heart.
A bench of Chief Justice G Rohini and Justice Sangita Dhingra Sehgal gave the direction a day after coronary stent was notified by the Department of Pharmaceuticals (DoP) as a Schedule-I drug under Drug Price Control Order (DPCO), 2013, making it eligible for price control.
The DoP had yesterday issued a notification putting bare metal stents, drug-eluting stents and bio-resorbable scaffold or biodegradable stents in schedule-I of the DPCO. This means that the National Pharmaceutical Pricing Authority (NPPA) can now start the process of fixing ceiling prices for the devices.
The court had on December 7 asked the Centre as to why the MRP of coronary stents has not been fixed despite these devices being included in the national essential list of medicines (NLEM).
The court was hearing a PIL saying that the rate of the coronary stents has not been fixed despite it being included in the NLEM, 2015 by way of a notification issued on July 19 this
year.
The petition, which has been moved by a lawyer, has alleged that the government and the NPPA were being "insensitive and irresponsible" towards the people by not taking any steps to fix the price of such stents which are allegedly being sold at higher rates in the country.
The petitioner, Birender Sangwan, has claimed that people in all age groups in the country suffer from heart ailments requiring use of stents and not all of them can afford this treatment.
He has sought a direction to the NPPA "to control the rate and decide a particular maximum retail price (MRP) of the coronary stents".
The petition also seeks a direction to the Drug Controller General of India "for providing prompt availability of the coronary stents at medical stores to enable patients to have a quick access" to these devices.
The court has now fixed the matter for March 1 next year.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 22 2016 | 7:13 PM IST

Next Story